The poor aqueous solubility of drugs has emerged as a major issue for pharmaceutical scientists 30 from many decades. The current study explores the manufacture and development of a 31 thermodynamically stabilized solid crystal suspension (SCS) of poorly water soluble drug 32 efavirenz via hot melt extrusion. Efavirenz is a non-nucleoside reverse transcriptase inhibitor 33 and belongs to BCS class II. The SCS was prepared using pearlitol and xylitol as a crystalline 34 carrier. The drug-excipient blend was processed by hot melt extrusion with up to 50% (w/w) 35 drug loading. Physico-chemical characterization of the SCS conducted via a scanning electron 36 microscopy showed crystalline morphology. The solid state analysis undertaken by using 37 differential scanning calorimetry and hot stage microscopy confirmed that SCS are in 38 crystalline state. Similarly, X-ray powder diffraction analysis revealed that pure drug, 39 crystalline carriers and developed SCS are in crystalline state. The FTIR chemical imaging 40 analysis of SCS formulations showed a homogeneous drug distribution within respective 41 crystalline carriers while an advanced chemical analysis via atomic force microscopy and 42 Raman analysis complemented the foregoing findings of the FTIR imaging. The developed 43 SCS1 formulation showed up to 81 fold increase in the solubility and 4.1 fold increase in the 44 dissolution rate of the drug compared to that of the bulk substance. Surprisingly, the developed 45 SCS formulation remained stable for a period of more than one year at accelerated conditions 46
Introduction

53
In the recent years, hot-melt extrusion (HME) has been evolved as a promising 54 pharmaceutical manufacturing technology for a wide variety of pharmaceutical applications 55 such as taste masking of API (Maniruzzaman et al., 2014; ) , sustained oral drug delivery (Claeys 56 et al., 2015;), cocrystal drug delivery (Moradiya et al., 2014) . More recently HME has 57 successgfully been used as a continuous manufacturing technique by implementing the Quality 58 by design (QbD) and process analytical technology (PAT) paradigm (ref) . Different types of dies may be employed to obtain desired shape of extrudes via HME. Using these different types 60 of dies formulation products such as oral fast dissolving films, transmucosal, transdermal DDs 61 ( Park et al., 2015) , intravaginal DDs (Clark et al., 2012) , implants (Stanković et al., 2013) , 62 stents and ophthalmic inserts (Lee et al., 2010) have been manufactured and reported in 63 literature. There are several commercial products available in market to date primarily made 64 by HME and these include Ritonavir -Norvir ® (Sherman and Steinberg, 2011) , Ibuprofen - Recently, a new phrase called solid crystal suspensions (SCS) was proposed, which is 71 an intimate mixture of a crystalline drug with crystalline carrier resulting in the formation of a 72 stable formulation with significantly faster dissolution rate, comparative to pure drug using 73 HME (Reitz et al., 2013; Thommes et al., 2011) . In SCS, the crystalline drug is suspended in 74 crystalline carrier matrix without facilitating any interactions between the drug and the 75 crystalline matrices but producing a thermodynamically stable system. Unlike the starting 76 components, the newly formed crystallinelattice also completely differs from the traditional 77 solid dispersions (Chiou and Riegelman, 1971 ; Marsac et al., 2006) . The physical stability of 78 SCS is very high because of no existence of amorphous phase in the system , compared to other 79 types of traditional solid dispersions (Thommes et al., 2011; Urbanetz, 2006) . The increase in 80 dissolution rate by SCS approach is due to API particle size reduction within the highly soluble 81 crystalline carrier and improvement in wettability and thus the solubility. 82 EFV is used as a part of highly active antiretroviral therapy (HAART) in the treatment 83 of human immunodeficiency virus (HIV) type 1 disease. It is a white, crystalline, non-84 hygroscopic powder which is insoluble in water (Zakeri-Milani et al., 2009). Hence, there is 85 strong need to overcome the issue of poor solubility of EFV in order to enhance oral 86 bioavailability. It has been reported in literature that various polyols, superdisintegrants and 87 polymers can be used as a carrier in HME for solubilization of poorly water-soluble drugs The aim of the study was to explore SCS concept for poorly water-soluble drug EFV 91 using highly soluble crystalline carriers by HME technology. In this context, we report the 92 formation of crystalline molecular dispersions of poorly water-soluble drug Efavirenz (EFV)..
In the present study, we also have explored polyols such as xylitol and mannitol as a crystalline 94 carrier for SCS formation, due to their rapid crystallization behaviour (Cares-Pacheco et al., 95 2014)as reported earlier (Thommes et al., 2011 Micro compounder (Thermo scientific, Newington, NH, USA) with co-rotating twin screws.
126
Optimized batches were taken in the ratio of EFV to either xylitol or pearlitol by preparing 128 physical mixture using mortar-pastle. HME was performed having drug to carriers in 20:80 129 and 50:50 ratio of both the polyols as shown in table 2.
130
Accurately 20 gm powder physical mixtures were prepared and extruded through the 1 131 mm diameter die at optimized temperature with 100 rpm speed (Chen et al., 2006) . For melt 132 extrusion with pearlitol, the extrusion was carried out at temperature 138-140°C, (melting point The EFV and SCS were analysed for saturation solubility study in 0.1N HCl containing 146 0.2% sodium lauryl sulfate (SLS) maintained at 37 ± 0.5 °C. Excess amounts of API and SCS 147 were added to 10 ml of dissolution media and capped glass test tubes were kept in a shaking 148 incubator (Boekel scientific, USA) maintained at 37±0.5°C with75 rpm speed for 48 hrs. The 149 solutions in the test tubes were vortexed and kept for centrifugation at 5000 rpm for 10 min.
150
The supernatant layer was then filtered through 0.45µm millipore membrane filter and 151 analyzed for drug content by HPLC. The study was carried out in triplicate. The In vitro dissolution studies were conducted using a USP type II dissolution 155 apparatus. From SCS amount equivalent to 100 mg of EFV was filled into capsules and the 156 capsules were then placed in sinker and put into dissolution medium within the apparatus. The samples were analysed using UV-spectrophotometer at 248 nm. The dissolution studies were 162 performed in triplicate. The powder sample was placed on temperature-controlled stage. Position of the accessories 200 were adjusted such that a good focused image was obtained. The spectrometer was setup in 201 attenuated total reflectance (ATR) mode using a diamond internal reflection element (IRE).
202
The images were acquired with a spectral resolution of FTIR 0.2 cm −1 and 32 co-added scans 203 by using OPUS ® 6.5 software with an acquisition time of approximately 2 min. Differential scanning calorimetry and powder XRD studies were carried out to determine 260 crystallinity of EFV SCS at 0, 6 and 12 months. The in vitro dissolution studies also carried 261 out to study the percentage drug release of aged SCS samples. 
272
TGA studies revealed that EFV, xylitol and pearlitol were stable under the employed extrusion 273 conditions and exhibited less than 2% weight loss, when subjected to heat ramp (Fig.1 ). In this 274 context, all formulations were processed below 150°C temperature, henceforth it was 275 concluded that processing temperatures studied were suitable during the HME process. The SCS formulation approach developed by HME process, results in the formation of 291 a suspension of API in molten carrier system of polyols. The molten xylitol found somewhat 292 better solvent for EFV due to its relatively lowermelting point (94-96 °C) and acts as a better 293 carrier to make a molten mass with EFV resulting in formation of solid crystal suspensions.
294
The improved solubility of EFV SCS results due to improved wettability and reduced particle 295 size. The extrusion process results in to reduction in particle size of drug (Reitz et al., 2013). 296 Remarkably, SCS2 and SCS4 formulations reveals smaller particle size than that of 297 with SCS1 and SCS3. The smaller particle size of SCS2 and SCS4 is ascribed to lower shear 298 forces in 20% drug loaded formulations, which exhibits, having availability of higher 299 proportion of molten xylitol and pearlitol in formulation mixture during hot melt extrusion 300 processing ( Thommes et al., 2011) . In extrusion process, the intense mixing and agitation of The invitro dissolution studies were conducted to assess the performance of SCS 311 formulations compared to pure EFV. The Fig. 3 indicates dissolution profiles of pure EFV, 312 SCS formulations and marketed capsule EFAVIR ® . It has beenreported in literature that the 313 bulk EFV has an aqueous solubility of 5.2 ± 0.3 µg/mL (Maurin et al., 2002) . It can be seen 314 that pure EFV showed slow dissolution rates of 22% at 45 min, 24% at 90 min. In contrast, all 315 SCS formulations showed significant increase in dissolution rate of more than about 70% at 316 the end of one hour. Optimized batch i.e. SCS1 (20% EFV) and SCS2 (50% EFV) formulated 317 with xylitol showed the dissolution of 100% and 93%, respectively in 1hr, which is 318 approximately 4.1 and 3.9 folds higher than that of pure EFV. In addition, the SCS3 (20% 319 EVF) and SCS4 (50% EVF) made using pearlitol showed slightly slower dissolution of 88% 320 and 82%, respectively after 1 hr. In all formulations, dissolution rate has been significantly 321 improved compared to that of pure EFV (P < 0.05). The corresponding physical mixture of 322 EFV with xylitol and pearlitol showed little increase in dissolution rate. However, dissolution 323 from physical mixture is not as effective as that from the developed SCS formulation. The 324 marketed EFAVIR ® capsule showed 98% drug release in 1 hr, which is similar to that of the 325 optimized SCS formulation (P < 0.05 Fig.3) . 326 It is expected that the solid crystal suspensions prepared of crystalline materials will 327 enhance the physical and chemical stability of the drug. Therefore, the stability studies 328 conducted at accelerated condition for 6 months showed no significant change in the release of 329 the crystalline poorly soluble EVF.The Fig.4 shows dissolution profiles of SCS1 and SCS3 formulations kept for accelerated stability conditions (40° C/ 75% RH) at day 1, 6 months and 331 12 months. Differences in dissolution profiles between fresh and 12 month's stored samples 332 are statistically non-significant (P< 0.05). The formulations SCS3 and SCS4 produced using 333 pearlitol can be considered physically stable. In contrast, SCS1 showed statically significant 334 difference (P < 0.2) in dissolution profiles during the storage at the accelerated condition. The 335 SCS prepared from xylitol showed physical and chemical instability and showed decrease in 336 dissolution rate (Rowe et al., 2009 ). This could be attributed to the nature of the possible 337 interaction between the drug and the crystalline excipients during the extrusion. (Fig 5b) showed a sharp endotherm at 92.8°C corresponding to its melting 344 and confirming its crystalline nature. Pearlitol showed a sharp endotherm peak 164.8°C 345 inferring to its crystalline nature. In case of all SCS formulations, two melting endotherms have 346 been seen (Fig 5c, d, f,g) . The melting endotherm of xylitol and pearlitol were found broadened 347 with less intensity and were shifted to slightly lower temperature compared to the bulk 
Hot stage microscopy:
359 HSM studies were conducted to visually determine the thermal transitions and extent 360 of melting of EFV, SCS1 and SCS3 extrudates prepared by HME. Fig. 6A (EFV) , Fig. 6B 
361
(SCS1) and Fig. 6C (SCS3) infers the melting pattern at different stages such as notation 1 362 infers initial melting, 2onset of melting and 3infers complete melting of the respective 363 extrudate and pure EFV and SCS formulations at different points as shown in Table 3 .
The hot stage microscopy results are in good agreement with DSC results as the 365 complete melting of respective substances was as same as DSC endotherm peaks. HSM 366 technique has advantage as this microscopic method can be applied to more mixture systems 367 compared to other analytical methods due to fewer assumptions involved (Yang et al., 2011) .
368
The marked temperature at left bottom corner of each screen indicates temperature of sample 369 (A1-intinal melting, A2-onset of melting, A3-complete melting). The desolvation of respective to the presence of the crystalline drug and the sugar (Fig. 8) . Fast crystallization of the 393 excipients having high melting points is a critical element for producing crystal suspensions.
394
Xylitol having melting point of 96 -97° C exhibited better carrier system than that of pearlitol 395 with melting point of 165° C, where the drug was melted and adsorbed in the carrier system.
396
The SCS3 and SCS4 showed sharp diffractogram peaks resembling the EFV, which was 397 present in higher EFV loads. The FTIR spectra's of EFV, xylitol, pearlitol and SCS system are depicted in Fig. 9 . 401 The FTIR spectra of EFV Fig. (9a) showed characteristics peak of 3314 cm -1 (-NH stretch), 402 1742 cm -1 (C=O stretch), 1492 cm -1 (C ≡ C benzene ring stretch), 1240 cm -1 (-CN stretch), 1165 403 cm -1 (CO stretch), 1096, 1057 and 1074 (C-O-C stretch) and 689 and 652 cm -1 (-CF stretch).
404
Xylitol Fig. (9b) as well as pearlitol Fig. (10e) showed characteristics broad peak at 3100 -405 3400 cm -1 resembling the maximum number of hydroxyl moieties (-OH stretch). In addition to 406 that 1165 cm -1 (-CO stretch), 1050 -1300 cm -1 confirms the carboxylic acid and alcohol groups 407 moieties. The FTIR spectra's of the developed SCS1 and SCS2 formulations are shown in Fig.   408 (9c, d) and SCS3 and SCS4 formulationsin Fig. (10 f, g) which infers the combination of 409 characteristics peak of EFV and respective polyols. These results resemblance that formation 410 of SCS system by HME did not result in any molecular interaction between EFV and respective 411 carriers (Thommes et al., 2011) . The characteristics broad peak stretch at 3100 -3400 cm -1 412 (shown by dotted rectangle) was retainedin the SCS system inferring to maximum number of 413 hydrophilic groups, which has been provided by hydrophilic carriers (Pawar et al., 2015) . The 
Conclusions
488
HME has successfully been exploited to manufacture EVF based SCS as an effective 489 technique to increase the dissolution rate of poorly water soluble drug. In this emerging 490 approach crystalline drug substance is keept in its crystalline state. The use of mannitol and 491 xylitol as crystalline carriers showed a faster drug release compared to that of the bulk drug .
492
The optimized SCS1 formulation system showed 19-81 fold improvement in the solubiltiy two 493 different dissolution media and likewise the dissolution rates. The DSC and XRD analysis 494 confirms that drug is present in stabilized crystalline form in the developed SCS formulation.
495
FTIR analysis showed no chemical interaction between the API and sugar alcohols 496 respectively. FTIR chemical imaging analysis has also confirmed the homogenous dispersions 497 of the drug molecule into the sugar matrices. It can be concluded that the"solid crystal 498 suspension" approach by means of HME can be adopted as an alternative emerging technique 499 particularly suitable for those drugs that are difficult to stabilize in amorphous form. 
